Overview

Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This study will be conducted in subjects with refractory colorectal carcinoma with unresectable liver metastases. The purposes of the study are: - to evaluate the safety and any harmful effects of an intravenous injection of Ad.hIFN-β; - help determine whether the virus carrying the interferon-beta gene will enter the bloodstream and liver tumor cells and cause the cancer cells to die.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Biogen
Treatments:
Interferon-beta
Interferons